Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations

Introduction: V600E BRAF mutation is an established driver mutation in a variety of tumors. Vemurafenib is a selective inhibitor of the BRAF V600E kinase, known to be highly effective in BRAF V600E-positive metastatic melanoma. As a single agent, vemurafenib is relatively ineffective in other V600E-...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Biol Ther
Asıl Yazarlar: Ofir Dovrat, Tali, Sokol, Ethan, Frampton, Garrett, Shachar, Eliya, Pelles, Sharon, Geva, Ravit, Wolf, Ido
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Taylor & Francis 2018
Konular:
Bedside to Bench Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6300338/
https://ncbi.nlm.nih.gov/pubmed/30036146
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2018.1480289
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller